GRI Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases. The company’s focus is on addressing significant unmet medical needs in the United States through a pipeline of novel therapeutic candidates designed to target complex disease mechanisms.
The company’s lead product candidate, GRI-0621, is currently in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring of lung tissue. GRI-0621 aims to provide a new therapeutic option for patients suffering from this debilitating condition. Additionally, GRI Bio is advancing GRI-0803, which is in Phase I clinical trials for the treatment of systemic lupus erythematosus (SLE), an autoimmune disorder that affects multiple organs and systems in the body.
GRI Bio’s development pipeline also includes GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease characterized by inflammation and scarring of the bile ducts. Another candidate, GRI-0729, is also in pre-clinical development, with potential applications in treating various fibrotic and autoimmune conditions. The company is also working on ADAIR and ADMIR, therapeutic candidates aimed at addressing attention-deficit/hyperactivity disorder (ADHD), expanding its therapeutic focus to neurodevelopmental disorders.
Formerly known as Glycoregimmune, Inc., GRI Bio, Inc. was founded in 2009 and is headquartered in La Jolla, California. The company’s rebranding reflects its commitment to advancing its innovative therapies and expanding its pipeline. GRI Bio continues to leverage its expertise in drug development to deliver effective treatments for complex and challenging diseases, positioning itself as a key player in the biopharmaceutical industry.
|
